

RETRACTION



Retraction: Syringaresinol mitigates cerebral ischemia-induced brain injury via NF- κ B pathway inhibition and glial cell deactivation

Signa Vitae Editorial Office^{1,*}

¹MRE Press No. 50 Tagore Lane, 03-01 (H), 787494 Singapore, Singapore

*Correspondence

Editor@signavitae.com (Signa Vitae Editorial Office)

After publication, post-publication review by the Editorial Office revealed that the article [1] (DOI: 10.22514/sv.2025.027) contained a number of irrelevant citations and, in some cases, lacked appropriate citations (*e.g.*, [1], [2], [5], [8], [20], [23]). These irrelevant citations compromise the validity of the introduction and discussion sections and undermine the overall trustworthiness of the published work.

The authors were notified of the concerns and the intention to retract the article on multiple occasions but did not respond to any correspondence from the Editorial Office.

Accordingly, the editors have decided to retract the article. This Retraction has been approved by the Editor-in-Chief. The original article PDF remains available with a “RETRACTED” watermark for transparency. This retraction has been issued to preserve the integrity of the scholarly record.

REFERENCES

- [1] Wang CF, He XY, Taximaimaiti R, Zhang CL, Li HY. Syringaresinol mitigates cerebral ischemia-induced brain injury via NF- κ B pathway inhibition and glial cell deactivation. *Signa Vitae*. 2025; 21: 111–117.